Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Sophia Genetics SA(SOPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SOPH
11/06/2026: SOPH (1-star) is currently NOT-A-BUY. Pass it for now.
Sophia Genetics is a cloud-based health technology company that uses AI to provide clinical insights from genomic and radiomic data. The stock is a growth-oriented play in the precision medicine market, benefiting from a platform-agnostic business model that serves a global network of hospitals. Its primary opportunity lies in expanding its footprint within pharmaceutical research and medical imaging diagnostics. However, investors face risks from significant competition, ongoing operational losses, and potential regulatory shifts in healthcare reimbursement. Given its pre-profit status and high volatility, this stock is most suitable for long-term growth investors who should monitor the company's path toward consistent operating profitability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in the high-growth precision medicine sector with a scalable software-as-a-service (SaaS) model. |
| Momentum investor | Mixed fit | Fit is conditional on positive market sentiment and sustained revenue acceleration. |
| Value investor | Weak fit | The company is not currently profitable, making traditional value metrics like P/E ratios inapplicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on capital reinvestment. |
| Low-risk investor | Weak fit | The stock exhibits high price volatility and the business is still in a high-risk growth stage. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a growth-stage biotech stock, shares are susceptible to sharp fluctuations based on market sentiment and earnings misses. |
| Valuation risk | Medium / high | Valuation is sensitive to long-term growth expectations rather than current earnings. |
| Competition risk (AI competition) | High | Technological advancements from legacy diagnostics giants and AI-native startups pose a continuous threat to market share. |
| Business quality | Medium | While the platform-agnostic software model is robust, the company has yet to reach consistent profitability. |
| Dividend income | Low / none | Investors should expect zero income from this position. |
| Execution risk | Medium / high | Successfully expanding the product suite into biopharma and imaging requires flawless execution across diverse regulatory environments. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 19.83% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 611.60M USD | Price to earnings Ratio - | 1Y Target Price 9.75 |
Price to earnings Ratio - | 1Y Target Price 9.75 | ||
Volume (30-day avg) 646.5K shares | Beta 1.09 | 52 Weeks Range 3.83 - 8.98 | Updated Date 11/07/2026 |
52 Weeks Range 3.83 - 8.98 | Updated Date 11/07/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Analytical SaaS | Recurring revenue from hospital and lab subscriptions to the SOPHiA DDM platform. | The company earns money through a platform-as-a-service model, similar to cloud software companies, based on usage. |
| Biopharma Services | Contracts with pharmaceutical companies for clinical trial patient identification and research analysis. | This segment provides high-value, research-oriented revenue which is a key growth lever. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 537.44M | Price to Sales(TTM) 6.72 |
Enterprise Value 537.44M | Price to Sales(TTM) 6.72 | ||
Enterprise Value to Revenue 5.91 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 85.66M | Shares Floating 65.88M |
Shares Outstanding 85.66M | Shares Floating 65.88M | ||
Percent Insiders 7.2 | Percent Institutions 60.38 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.